Abstract:<section class="article-section__content"><h3 class="article-section__sub-title section1"> Background</h3><p>Due to the biological heterogeneity, 60%–70% of patients with major depressive disorder (MDD) do not respond to or achieve remission from first‐line antidepressants. Predicting neuroimaging biomarkers for early antidepressant treatment could guide initial antidepressant therapy.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Purpose</h3><p>To assess for neuroimaging biomarkers for antidepressant selection in early antidepressant treatment.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Study Type</h3><p>Prospective.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Subjects</h3><p>A total of 85 MDD patients from the major site and 33 MDD patients from an out‐of‐sample test site.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Field Strength/Sequence</h3><p>A 3.0 T, T1‐weighted imaging using a magnetization‐prepared rapid acquisition gradient‐echo sequence and diffusion tensor imaging (DTI) using an echo‐planar sequence.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Assessment</h3><p>Baseline DTI data of patients who achieved early improvement after 2‐weeks of antidepressant treatment (selective serotonin reuptake inhibitors [SSRI] or serotonin‐norepinephrine reuptake inhibitors [SNRI]) were analyzed. An ensemble model was constructed using data from the major site and then applied to assess the early response of patients at the out‐of‐sample test site.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Statistical Tests</h3><p>Support vector machine combined with leave‐one‐out cross‐validation were applied to construct the whole model from individual base models from different brain regions. Discriminative biomarkers were evaluated by calculating the changes in sensitivity and specificity obtained when removing a single base model from the whole model, the base model being removed changing in each run.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Results</h3><p>Training performance over MDD patients at the major site achieved 75% accuracy while performance with accuracy of 70% was achieved in the out‐of‐sample test site. Assessing sensitivity and specificity changes following the removal of single base models from the prominent model highlighted the functions of two neural circuitries: SSRI‐related emotion regulation circuitry, centered on the hippocampus (sensitivity changes: 10%) and amygdala (sensitivity changes: 11%); and SNRI‐related emotion and reward circuitry, centered on the putamen (specificity changes: 8%) and orbital part of superior frontal gyrus (specificity changes: 12%).</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Data Conclusion</h3><p>These findings support future research on clinical antidepressant selection for MDD.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Evidence Level</h3><p>1</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Technical Efficacy</h3><p>Stage 2</p></section>

An Investigation into the Association Between Dopamine Receptor D1 Multilocus Genetic Variation, Multiparametric Magnetic Resonance Imaging, and Antidepressant Treatment

Links among Genetic Variants and Hierarchical Brain Structural and Functional Networks for Antidepressant Treatment: A Multivariate Study.

Mediating Role of the Reward Network in the Relationship between the Dopamine Multilocus Genetic Profile and Depression.

Mediating Role of the Reward Network in the Relationship Between the Dopamine Multilocus Genetic Profile and Depression

A Joint Study of Whole Exome Sequencing and Structural MRI Analysis in Major Depressive Disorder.

Dopamine Multilocus Genetic Profile, Spontaneous Activity of Left Superior Temporal Gyrus, and Early Therapeutic Effect in Major Depressive Disorder

Sub-hubs of Baseline Functional Brain Networks Are Related to Early Improvement Following Two-Week Pharmacological Therapy for Major Depressive Disorder.

Combination of Spontaneous Regional Brain Activity and HTR1A/1B DNA Methylation to Predict Early Responses to Antidepressant Treatments in MDD

Influence and interaction of genetic, cognitive, neuroendocrine and personalistic markers to antidepressant response in Chinese patients with major depression

The role of single nucleotide polymorphism of D2 dopamine receptor gene on major depressive disorder and response to antidepressant treatment.

Influence and interaction of resting state functional magnetic resonance and tryptophan hydroxylase-2 methylation on short-term antidepressant drug response

Catecholamine Pathway Polymorphisms and Antidepressant Response.

Serotonin 2A Receptor Polymorphism Rs3803189 Mediated by Dynamics of Default Mode Network: a Potential Biomarker for Antidepressant Early Response.

Targeted Exome Sequencing Identifies Five Novel Loci at Genome-Wide Significance for Modulating Antidepressant Response in Patients with Major Depressive Disorder

Epistatic Interaction Between 5-HT1A and Vascular Endothelial Growth Factor Gene Polymorphisms in the Northern Chinese Han Population with Major Depressive Disorder

Shared and unique imaging-derived endo-phenotypes of two typical antidepressant-applicative depressive patients

Predicting Neuroimaging Biomarkers for Antidepressant Selection in Early Treatment of Depression

Distinct MRI-based functional and structural connectivity for antidepressant response prediction in major depressive disorder

Optimizing Antidepressant Efficacy: Generalizable Multimodal Neuroimaging Biomarkers for Prediction of Treatment Response

The Role of BDNF, NTRK2 Gene and Their Interaction in Development of Treatment-Resistant Depression: Data from Multicenter, Prospective, Longitudinal Clinic Practice

Association between polygenic risk scores combined with clinical characteristics and antidepressant efficacy